SS Innovations International Business Summary

SS Innovations International, Inc. (SSII) operates as a commercial-stage medical technology firm specializing in the development and global distribution of cost-effective surgical robotic systems. The company generates revenue through a multi-tiered model comprising capital equipment sales of its flagship SSi Mantra system, recurring sales of SSi Mudra proprietary instruments and consumables, long-term service warranties, and flexible leasing arrangements. Its primary business segments include robotic hardware, advanced endosurgical instrumentation, and digital health platforms such as the SSi Maya XR simulator and tele-proctoring services. Positioned as a modular and affordable alternative to high-cost incumbents, SSII competes directly with industry leaders such as Intuitive Surgical, Medtronic, CMR Surgical, and PROCEPT BioRobotics, carving out a market niche by targeting underserved healthcare sectors in emerging markets and expanding into the U.S. and European territories. The company was founded by Dr. Sudhir Srivastava, a globally recognized pioneer in robotic cardiac surgery who has performed the world's largest number of robotic cardiothoracic procedures, alongside Dr. Vishwa Srivastava, who serves as CEO of the APAC region. The leadership team was significantly bolstered in January 2026 with the appointment of Milan Rao, a former GE Healthcare and Wipro executive, as Global COO and CFO, while Barry F. Cohen oversees operations in the Americas and Rama Krishna Reddy serves as CTO for South Asia. Notably, the board features Vice Chairman Dr. Frederic Moll, the legendary founder of Intuitive Surgical and Auris Health, and former ISRO director Dr. Mylswamy Annadurai. SSII has attracted institutional backing from prominent investors including Goldman Sachs, PNC Financial Services, and Handelsbanken Fonder, reflecting strong market confidence in its mission to democratize robotic-assisted surgery.